

DORSET MEDICINES ADVISORY GROUP

Recommendation Summary



**Dorset
Clinical Commissioning Group**

The Dorset Medicines Advisory Group (DMAG) includes representatives from the four provider Trusts, Public Health Dorset and GPs within the Clinical Commissioning Group (CCG). It advises the system on prescribing and commissioning of medicines in Dorset.

Summary of recommendations made by the group 14th July 2020. Formulary entries and associated documents can be accessed at www.dorsetformulary.nhs.uk.

PRODUCT	DECISION		COMMENTS
	Previous position	Recommended position	
1. Products re-categorised			
Betamethasone and neomycin (Betnovate N [®]) cream	Green	Amber	Only to be used on the advice of a specialist. A SystemOne pop up for primary care to be considered highlighting potency of steroid and antimicrobial ingredients, alongside recommended duration of use.
Hydrogen Peroxide 1% cream	Red	Green	In accordance with the recommendations within NICE NG153.
Osvaren [®]	Non-Formulary	Red	Work is still ongoing to finalise the Shared Care Guideline (SCG) which will support use of licenced and off-licence use. Until the SCG is developed and approved by the group, Osvaren [®] is approved as Red
Solifenacin	Green 2 nd line	Green 1 st line	
Oxybutynin IR	Green 1 st line	Green 2 nd line	NICE NG 123: Do not offer oxybutynin (immediate release) to older women who may be at higher risk of a sudden deterioration in their physical or mental health
Oxybutynin patch	Amber	Green alternative choice	Not for elderly patients, as per SPC

PRODUCT	DECISION		COMMENTS
Duloxetine	Green 2 nd line	Amber	
Darifenacin MR	Green 1 st line	Non-Formulary	
Trospium MR	Green 2 nd line	Green 2 nd line	Updated to specify modified release only, within chapter 7.4.2 of formulary
Alprostadil injection	Green and Red	Amber	
Propranolol (Chapter 04-07-04-02)	Non - Formulary	Green	This will allow primary care prescribing in accordance with NICE recommendations for prophylactic management of migraine.
Polyfax [®] ointment	Green	Non -Formulary	Product discontinued
2. New requests			
Cetraben [®] Ointment	Green		Formulary entry for Cetraben [®] will now include both cream and ointment
Minoxidil for hair loss	Non-Formulary		This includes the 5% minoxidil foam for the treatment of female pattern hair which has been added to the Drug Tariff
Elecare [®]	Amber		New addition to the Wessex infant feeding Guideline
Cutimed foam applicators	Green		To support the use of the foam.
Fremanezumab	Red		In line with NICE TA631 for preventing migraine
Avatrombopag	Red		In line with NICE TA626
Ustekinumab	Red		Additional indication added to formulary entry (Chapter 01-05-03) for treating Severely active ulcerative colitis in line with NICE TA633
Oxybutynin MR	Non-formulary		
Tolterodine MR	Non-formulary		
3. Products considered by NICE			

PRODUCT	DECISION	COMMENTS
<p>NICE TA631 Fremanezumab for preventing migraine NICE TA626 Avatrombopag for treating Thrombocytopenia in People with Chronic Liver Disease Needing a Planned Invasive Procedure. NICE TA633 Ustekinumab for treating Moderately to Severely Active Ulcerative Colitis. NICE TA637 Ranibizumab for treating diabetic retinopathy (terminated appraisal)</p>		
4. Miscellaneous recommendations by DMAG		
Ingenol mebutate gel (Picato®) and diclofenac gel (Solaraze®)	Removal from the actinic keratosis guideline	Based on the withdrawal of Picato® and non-formulary status of Solaraze®.
All antimicrobial bath and shower emollient products	Approved the addition of ‘Age restriction of under one year or patients with severe conditions’	Resources to support appropriate use or discontinuation of all bath and shower emollients available for primary care
Tranexamic Acid Injections	Approved the additional wording to be added to the formulary entry	‘Use of injection in primary care is anticipated to be in accordance with the palliative care handbook only’
Ranitidine	Approved the additional wording to be added to the formulary entry	‘During the shortage of ranitidine, you can supply cimetidine, nizatidine or famotidine as a last resort’.
Co-codamol capsules to tablets and ramipril tablets to capsules (exception if vegetarian/vegan).	Approved to make clear on the Formulary the preferred formulations	
Oxycodone MR tablets	The statement “for primary care only – branded prescribing required via EPS, recommended brands are Longtec® and Oxylan®” was approved to be added to the formulary	

PRODUCT	DECISION	COMMENTS
Doxazosin (chapter 07.04.01)	Approved removal of the following wording 'Doxazosin is green and MR preparations are licensed for BPH'	
5. Further Assessment / Evidence Required		
Working Group Terms of Reference		Awaiting final comments
System Governance Document		Awaiting final comments
Pathway for the Evaluation of Drugs in Dorset		Awaiting final comments
Ospemifene	Ospemifene proposal as green (From Red) as stated on the formulary proposal was not approved	Questions were raised about the clinical and cost-effective evidence for ospemifene, and the long-term impact for the health economy if prescribing was to move across to primary care in the future.
PICO 7 & PICO 7Y	Not approved	For use on acute, surgical wounds in accordance with NICE MTG 43 this will be for Trust determination. For chronic wounds it was agreed that the group would link with the nurse specialist in the CCG quality team to determine where this option sits within a commissioned pathway.
6. New documents approved		
Annual Report 2019-2020 Attendance Log for 2019-2020 Dorset GP review of fibrate prescribing 2020-21 document Supporting statement for the NHS England guidance on the supply of additional direct oral anticoagulants (DOACs) during COVID-19		

PRODUCT	DECISION	COMMENTS
<p>Biologics Decision Aid in Psoriasis</p> <p>Commissioning Statement on the use of Fremanezumab for Preventing Migraine (NICE TA631)</p> <p>Commissioning Statement on the use of Avatrombopag for Treating Thrombocytopenia in People with Chronic Liver Disease Needing a Planned Invasive Procedure (NICE TA626)</p> <p>Commissioning Statement for Ustekinumab for Treating Moderately to Severely Active Ulcerative Colitis In accordance with NICE TA633</p> <p>The venous thromboembolism: diagnosis and anticoagulation treatment visual summary link</p> <p>Urinary incontinence formulary Guideline</p>		
<p>7. Documents Reviewed</p>		
<p>DMAG Terms of Reference (to go to CRG for approval)</p> <p>Formulary Working Group Terms of Reference</p> <p>Formulary Proposal Form</p> <p>Shared Care Guideline for low-molecular weight heparin</p> <p>In Focus documents for Emollients</p> <p>In Focus documents for Bath Emollients</p> <p>Commissioning statement on the use of Modified Release Hydrocortisone (Plenadren®) for the Treatment of Adrenal Insufficiency</p> <p>Commissioning statement on Pevanti® (prednisolone)</p> <p>In Focus documents for Glucose Monitoring</p> <p>Shared Care Guideline for prescribing Anagrelide for use in Control of Thrombocytosis in Essential Thrombocythaemia</p> <p>Statement regarding prescribing of sterile dressing packs in primary care</p> <p>The Wessex Infant Feeding Guideline Link</p>		

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use on specialist advice with shared care arrangements

'AMBER' drugs suitable for use on specialist advice without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care
'Not Recommended' – drugs not recommended for use in Dorset